ABCA-1 elevating compounds

A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of increasing ABCA-1 expression, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I:

• wherein:
• R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• A is a covalent bond, C(X1)—, or —C(X1)—NH—, where X1 is oxygen or sulfur,
• R2, R3, R4 and R5 are independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halo, or optionally substituted cycloalkyl;
• X is oxygen, sulfur, —C(X1)—, or —NH—;
• Y is optionally substituted lower alkylene when X is oxygen or sulfur;
• or
• Y is —NH— when X is —C(X1)—;
• or
• Y is —C(X1)— when X is —NH—;
• with the proviso that X and Y cannot both be —NH—;
• R6, R7, R8, R9, and R10 are independently hydrogen, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• or
• R6 and R7, or R7 and R8, or R8 and R9, or R9 and R10, taken together with the carbon atoms to which they are attached form 5 or 6 membered heterocyclyl, heteroaryl, cycloalkyl, or an aromatic or non-aromatic carbocyclic moiety, all of which are optionally substituted by halo, alkyl, alkenyl, alkynyl, alkoxy, or cycloalkyl;
• with the proviso that when Y is —NH— and X is —C(X1)—, or when Y is —C(X1)— and X is —NH—, A cannot be —C(X1)—NH—.